In early 2026, Moderna reported encouraging long-term data for its personalized cancer vaccine mRNA-4157 (V940) in high-risk ...

They aren't just "pandemic stocks." ...

In the latest trading session, Moderna (MRNA) closed at $51.38, marking a -1.89% move from the previous day. This change ...

The list is topped by Moderna, Inc. ( MRNA ), with a YTD performance of 73.89%. DaVita Inc. ( DVA) and Revolution Medicines, ...

Incentives to bring vaccines to market are shrinking. Drugmakers are scaling back research investments and cutting jobs.

If you are wondering whether Moderna's share price really reflects what the business is worth today, you are not alone. That ...

Two stocks are standing out in premarket trading this Wednesday morning. Moderna (Nasdaq: MRNA) is up 8.9% and Ross Stores (Nasdaq: ROSS) is up 6.6% as of 8:00 AM ET, each moving on a distinct ...

Moderna (NASDAQ:MRNA) has agreed to pay US$950 million to resolve a long-running patent dispute tied to the technology used in its COVID-19 vaccine. The pharmaceuticals giant announced it has reached ...

Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an ...

The U.S. Food and Drug Administration (FDA) recently informed Moderna that it would not review the company’s application for ...

After the Food and Drug Administration initially declined to review Moderna's mRNA flu vaccine candidate, the drugmaker said Wednesday that the FDA reversed its decision and will allow Moderna to move ...

Targets readouts from nine ongoing Phase 2 and Phase 3 clinical studies in its oncology pipeline, including three Phase 3 programs for intismeran autogene Further improves 2026 and 2027 expected GAAP ...